Drug news
NICE does not recommend Humira (adalimumab) to treat hidradenitis suppurativa- AbbVie
The National Institute for Health and Care Excellence (NICE) has not recommended Humira (adalimumab) to treat hidradenitis suppurativa (acne inversa), a rare inflammatory skin condition, despite European approval based on the PIONEER II study. NICE found that the application submitted by AbbVie contained uncertain data and AbbVie has been asked to provide a meta-analysis of the PIONEER I and PIONEER II studies to help determine cost effectiveness.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.